The American Society of Clinical Oncology (the Society) is governed by a volunteer Board of Directors (including five Board officers) elected by ASCO’s member oncologists. The ASCO Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.

View the Disclosures for the Society Board of Directors at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to COI@asco.org.

Clifford A. Hudis, MD, FACP, FASCO
Chief Executive Officer, ASCO; Executive Vice Chair, Conquer Cancer, the ASCO Foundation; and Chair, CancerLinQ
x

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.

Read Dr. Hudis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Everett E. Vokes, MD, FASCO
ASCO President-Elect
x

Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly  Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

View current ASCO disclosure here

Lori J. Pierce, MD, FASTRO, FASCO
ASCO President
x

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015. 

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologoists’ Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

View current ASCO disclosure here.

Howard A. Burris III, MD, FACP, FASCO
Board Seat: Chair of the Board
x

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris will serve as the elected president of ASCO in 2019-2020. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.  

View current ASCO disclosure here.

Monica M. Bertagnolli, MD, FACS, FASCO
Board Seat: Past President
x

Dr. Bertagnolli is a professor of surgery at Harvard Medical School, and chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.

Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.

In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.

Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.

View current ASCO disclosure here.

Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO
Treasurer
x

Dr. Gaspar grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at Western University.  Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.

Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She is also involved with the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 published articles.

Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emerita in the Department of Radiation Oncology at the University of Colorado, as well as a staff radiation oncologist at Banner MDA in Northern Colorado.  Dr. Gaspar maintains a long-standing interest in the management of brain tumors and lung cancer.

Read Dr. Gaspar’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Ethan M. Basch, MD, MSc, FASCO
Board Seat: Undesignated Specialty
x

Dr. Basch is chief of the division of oncology at the University of North Carolina and physician-in-chief of the North Carolina Cancer Hospital. He is the Richard M Goldberg Distinguished Professor in Medical Oncology and professor of health policy & management. He serves as director of the cancer outcomes research program at UNC Lineberger Comprehensive Cancer Center, as associate editor at Journal of the American Medical Association, and on the editorial board of the Journal of Oncology Practice. He has previously served on the NCI Board of Scientific Advisors, on the Methodology Committee of PCORI, as chair of the ASCO Clinical Practice Guidelines Committee, the CancerLinQ Advisory Group, the Annual Meeting Education Committee, and the Quality of Care Council.

Read Dr. Basch’s Q&A on ASCO Connection.

View current ASCO disclosure here.

A. William Blackstock, MD, FASCO
Board Seat: Radiation Oncologist
x

Dr. Blackstock is Professor and Chair of the Department of Radiation Oncology at the Wake Forest University (WFU) School of Medicine and Director of the Clinical Research Program at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center. He received his undergraduate degree from WFU and his medical degree from the East Caroline University Brody School of Medicine. He completed a residency in radiation oncology at the University of North Carolina at Chapel Hill and a three-year NCI-funded fellowship in translational Radiation Oncology. He has been Chair at WFU for the past 8 years.

Dr. Blackstock remains active in translational clinical research, having served as vice-chair of the GI Committee in the Alliance/CALGB cooperative group and co-vice chair of the Radiation Oncology committee. In addition to serving on the NCI Clinical Oncology study section (2003-2006), he served on the NCI Pancreatic Task Force, Gastrointestinal Steering committee and co-chair of the Thoracic Malignancy Steering Committee (2013-2016). He recently completed service on the NCI Board of Scientific Counsel Intramural Program.

Dr. Blackstock has been an active ASCO member for almost 20 years, serving on the grants selection and communications committees. He has chaired the Gastrointestinal Cancer Program subcommittee and the ASCO membership committee (2008-2009). Other activities include participating in the ASCO Leadership Development Working Group and Health Disparities Advisory Group.

Dr. Blackstock has been the lead investigator of several NCI-funded grants including principal investigator of an NCI-funded T32 fellowship focused on Translational Radiation Oncology. He currently serves on the external advisory board for several NCI/NIH funded training programs. He has published over 100 peer-reviewed manuscripts and book chapters and continues to serve on the editorial board for several journals including the Journal of Clinical Oncology (2007-2009).

View current ASCO disclosure here.

Lisa A. Carey, MD, FASCO
Board Seat: Undesignated Specialty
x

Dr. Carey is Chief of Hematology/Oncology, Associate Director of Clinical Sciences, and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also Physician-In-Chief of the N.C. Cancer Hospital. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Journal of Clinical Oncology editorial board.

View current ASCO disclosure here

Lee M. Ellis, MD, FASCO, FACS
Board Seat: Undesignated Specialty
x

Dr. Ellis is the Ruben Distinguished Chair in Gastroenterology Cancer Research and a professor in the Departments of Surgical Oncology, and Molecular & Cellular Oncology at The University of Texas MD Anderson Cancer Center (MDACC), Executive Director for Translational Research, Global Academic Programs (MDACC), as well as the Vice Chair of Translational Medicine at SWOG. Previously, he served as Interim Chair, Department of Cancer Biology from 2008 to 2012, Director of the Metastasis Research Center from 2010 to 2012, and Director of the Colorectal Cancer Translational Research Program from 2007 to 2013, all at MDACC.

Since joining ASCO in 1994, Dr. Ellis has served on numerous committees with recent committee service on the Nominating Committee (2013-2016; chair, 2015-2016), the Best Practices in Clinical Cancer Trials Workshop (2015-2016), the Cancer Research Committee (2011-2014; chair 2012-3013), and the Cancer Education Committee (2011-2013; Tumor Biology track leader, 2012-2013). He served as a faculty member of the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2007-2013 and was co-director in 2010-2013. He was named a Fellow of ASCO (FASCO) in 2014, and he currently serves on the ASCO Board Liaison to the Cancer Research Committee (CRC) and Society Board’s Audit Committee.

In addition to his ASCO involvement, Dr. Ellis serves as the co-chair of the National Cancer Institute's (NCI) National Clinical Trials Network Core Correlative Sciences Committee (NCTN-CCSC), Vice Chair emeritus of the NCI Colon Cancer Task Force, and Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. He also serves on the board of directors of the Canines-N-Kids Foundation.  Dr. Ellis has a special interest in preclinical data reproducibility, and has published several important manuscripts in this area. He has also met with NCI, NIH, and National Academies of Science (NAS) leaders regarding the importance of this issue and how to address this problem. Dr. Ellis has also served on a NAS committee that focused on issuing recommendations to decrease the regulatory burden of research (2014-2016), and as faculty and then co-director (2015-present) of the AACR-EORTC-ESMO workshop on Methods in Clinical Cancer Research in Europe. In 2017, Dr. Ellis received the Flance-Karl Award from the American Surgical Association for his “seminal contributions in understanding colorectal cancer biology.” He currently serves on several data safety monitoring committees, including the ECOG/ACRIN DMC, and he is a member the Scientific Audit Committee of the EORTC (Brussels, Belgium).

Dr. Ellis received his medical degree from the University of Virginia; he performed his residency at the University of Florida, and his fellowship at MDACC.

Read Dr. Ellis’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Tara O. Henderson, MD, MPH, FASCO
Board Seat: Pediatric Oncologist
x

Dr. Henderson is an associate professor of pediatrics,  director of the Childhood Cancer Survivor Center at the University of Chicago, and director of survivorship for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee and a past member of multiple ASCO committees, such as the Conquer Cancer Grants Selection Committee.

View current ASCO disclosure here

Reshma Jagsi, MD, D.Phil, FASTRO, FASCO
Board Seat: Undesignated Specialty
x

Dr. Jagsi is Newman Family Professor and deputy chair of the Department of Radiation Oncology and Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan, where she is residency program director, treats breast cancer, and conducts health services research.

An ASCO member since 2004, Dr. Jagsi is a past chair of the Ethics Committee (member 2014-2016; chair 2014-2015). She has served on the Scientific Program Committee (2010-2012), and the Journal of Clinical Oncology (JCO) Editorial Board (2013-2015 and 2016-18). Dr. Jagsi participated in ASCO’s Leadership Development Program in 2011-2012 and served as an ASCO representative to the American Medical Association. She also served on the CancerLinQ® Data Governance Oversight Committee and the Bisphosphonates in Breast Cancer and Breast Cancer Consensus Expert Panels.

Dr. Jagsi leverages her research expertise to extend her ASCO service, having published in The New England Journal of Medicine, JAMA, and JCO on issues directly related to her ASCO committee and advocacy experiences. She has an active R01 grant from the National Cancer Institute to study the ethical implementation of CancerLinQ. She has also been active in ASCO’s efforts to promote gender equity (the subject of another R01-funded research program she leads), through its Women’s Networking Center.

Dr. Jagsi received her undergraduate and medical degrees from Harvard, and her doctorate in Social Policy from Oxford as a Marshall Scholar. She completed her residency at the Massachusetts General Hospital/Harvard Radiation Oncology Program (where she was chief resident), as well as a fellowship at the Harvard Center for Ethics.

Read Dr. Jagsi’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Michael P. Kosty, MD, FACP, FASCO
Board Seat: Community Oncologist
x

Dr. Kosty is a member of the Scripps Green Cancer Center where he has practiced hematology and medical oncology since 1989. He has served as the director of Scripps Green Cancer Center in La Jolla, California, since 2008, director of Graduate Medical Education at Scripps Clinic/Scripps Green Hospital since 2002, and as director of the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital since 1997. Since 1990, he has served at Scripps Green Cancer Center as head of the Thoracic Oncology Service, and as a member of the Genitourinary Oncology Service, Dermatologic Oncology Service, and the Clinical Research Advisory Committee.

Since joining ASCO in 1986, Dr. Kosty has served as the chair of the Continuing Medical Education Subcommittee (2013-2014), the Oncology Training Program Subcommittee (2009-2010) and the Workforce Advisory Group (2015-2016). In addition, he also served as a member of the Test Materials Development Committee and is ASCO co-chair of the European Society of Medical Oncology–ASCO Global Curriculum Workgroup. In recognition of his years of service to ASCO, Dr. Kosty received the distinction of Fellow of ASCO (FASCO) in 2014.

Dr. Kosty served as an investigator for the Southwest Oncology Group from 1999 to 2007 and as an investigator for the Cancer and Leukemia Group B from 1986 to 1999. Dr. Kosty dedicated many years to service in the military, as a general medical officer on the USS Belleau Wood (LHA-3; 1980-1981), as an attending physician and assistant head in the Division of Hematology/Oncology at the Naval Hospital (1986-1989), and as a member of the U.S. Naval Reserve (1989-1999).

Dr. Kosty received his undergraduate and master’s degrees from the University of California, Berkeley. He received his medical degree from George Washington University; he performed his internship, residency, and fellowship at Naval Hospital, San Diego. He was a visiting fellow at the Dana-Farber Cancer Institute at Harvard Medical School and a research fellow at the Scripps Clinic and Research Foundation.

Read Dr. Kosty’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Elizabeth A. Mittendorf, MD, PhD
Board Seat: Surgical Oncologist
x

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital, Associate Chair of Research for the Department of Surgery, and co-leader of the Breast Program at Dana-Farber / Harvard Cancer Center. She has previously served on ASCO’s Annual Meeting Scientific Program Committee and as chair of the Conquer Cancer Grants Selection Committee and is currently the chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Scientific Program Committee.

View current ASCO disclosure here.

Tony S. K. Mok, MD, FRCPC, FASCO
Board Seat: International Oncologist
x

Dr. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chair of Clinical Oncology at The Chinese University of Hong Kong (Hong Kong). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs Committee, Treasurer and Past President of the International Association for the Study of Lung Cancer (IASLC), a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Associate Editor on Thoracic Oncology for Journal of Clinical Oncology.  He has also authored eight books in Chinese and hosted three television series in Hong Kong.

Read Dr. Mok’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Elizabeth R. Plimack, MD, MS
Board Seat: Undesignated Specialty
x

Dr. Plimack serves as chief of the division of genitourinary medical oncology at Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.

Read Dr. Plimack's Q&A on ASCO Connection.

View current ASCO disclosure here.

Thomas G. Roberts, MD, FASCO
Chair, Conquer Cancer Foundation (ex-officio)
x

Dr. Roberts is a Managing Member and portfolio manager at Farallon Capital Management, LLC. Prior to joining Farallon, Dr. Roberts was an attending oncologist at Massachusetts General Hospital, an Instructor of Medicine at the Harvard Medical School, and a Visiting Scientist at Massachusetts Institute of Technology. Dr. Roberts obtained two baccalaureate degrees (Summa Cum Laude) from the University of Pennsylvania, including a Bachelors of Science from the Wharton School of Business (Phi Beta Kappa junior year). He obtained his medical degree from Harvard Medical School. Dr. Roberts performed his internal medicine training at the Massachusetts General Hospital and his medical oncology training through the Dana-Farber/Partners Cancer Care Oncology Fellowship Program. Dr. Roberts has been an ASCO member since 2003.

Read Dr. Roberts’ Q&A on ASCO Connection.

View current ASCO disclosure here.

Eric Jay Small, MD, FASCO
Board Seat: Medical Oncologist
x

Dr. Small is the deputy director and Chief Scientific Officer of the UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology. Dr. Small has worked at the University of California, San Francisco since 1988.

Since joining ASCO in 1992, Dr. Small has served as an associate editor for the Journal of Clinical Oncology (2008-2013), chaired the Molecular Markers Scientific Committee (2008-2009), chaired the Scientific Program Committee (2003-2004), served as the inaugural chair of the Prostate Cancer (Genitourinary Malignancies) Symposium Steering Committee, and served as chair of the Prostate Cancer (Genitourinary Malignancies) Symposium Program Committee (2004-2005). Dr. Small has chaired the grant writing workshop at the ASCO Annual Meeting. Dr. Small also served on the Nominating Committee (2007-2010) and the Conquer Cancer Foundation Grants Selection Committee (2009-2012), among other commitments. Dr. Small was named a Fellow of ASCO (FASCO) in 2015.

In addition to his ASCO involvement, Dr. Small has been a member of the National Cancer Institute Initial Review Group Subcommittee A (Parent Committee for Cancer Centers, 2010-2017), a member of the National Cancer Center Network Treatment Guidelines Panel (1999-2019), and has led a 40-member Stand Up to Cancer Dream Team. Dr. Small served as chair of the CALGB (Alliance) Genitourinary Committee for 14 years, and in 2011, was awarded the Richard L. Schilsky CALGB Award.  He serves as the chair of the External Scientific Advisory Boards for a number of NCI-designated cancer centers, including Fred Hutchinson/University of Washington; Knight Cancer Institute/OHSU; Moores Cancer Center/UCSD; and Sidney Kimmel Cancer Center/Jefferson University. 

Dr. Small received his undergraduate degree from Stanford University and his medical degree from Case Western Reserve University School of Medicine. He performed his internship and residency in internal medicine at Beth Israel Hospital (Boston), and completed his fellowship in Hematology/Oncology at the University of California, San Francisco, where he served as Chief of the Division of Hematology and Oncology for 10 years.

View current ASCO disclosure here.

Enrique Soto Perez De Celis, MD, MSc
Board Seat: International Oncologist
x

Dr. Soto is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. He currently serves on several ASCO committees, including the Annual Meeting Scientific Program Committee, Journal of Global Oncology Editorial Board, Social Media Working Group, Conquer Cancer Grants Selection Committee, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.

Read Dr. Soto’s Q&A on ASCO Connection.

View current ASCO disclosure here

Michael A. Thompson, MD, PhD, FASCO
Board Seat: Community Oncologist
x

Dr. Thompson is a medical oncologist and hematologist. He is the medical director for the Early Phase Cancer Research Program as well as the co-director of Oncology Precision Medicine Program at Advocate Aurora Health. He is a graduate of ASCO’s Leadership Development Program, has served as chair of the ASCO Annual Meeting Education Committee and the Research Community Forum Council, and is a current member of several ASCO volunteer groups.

Read Dr. Thompson’s Q&A on ASCO Connection.

View current ASCO disclosure here.

Tracey Weisberg, MD, FASCO
Board Seat: Community Oncologist
x

Dr. Weisberg is the past president and lead physician of New England Cancer Specialists for the past 10 years, manages an active breast cancer practice, has been a principal investigator on 40 clinical trials, and oversees medical house staff at the Maine Medical Center Oncology inpatient unit. An active member of ASCO since 1990, Dr. Weisberg is a past chair of the State Affiliate Council and has been involved in a number of ASCO initiatives, including the ASCO Rural Task Force, the CancerLinQ Advisory Committee, the Strategic Planning Task Force, and the Payment Reform Implementation Workgroup, to name a few.

Outside of ASCO, Dr. Weisberg has have served as a board member with Hospice of Southern Maine as well as Northern New England Oncology Association.

Read Dr. Weisberg’s Q&A on ASCO Connection.

View current ASCO disclosure here.